Journalistin-Stimmung Medien

Media Services

Tel.: +41 58 481 38 88

What’s new

Corona Zeichnung F. Loup

SARS-CoV-2 : Prospects for nasal spray vaccine

As part of the National Research Programme "Covid-19" (NRP 78) of the Swiss National Science Foundation (SNSF), researchers from Bern, Geneva, Berlin (GER) and Riems (GER) are developing two vaccine candidates against SARS-CoV-2. Thanks to a justsigned collaboration agreement with the Basel-based biotech company RocketVax AG, they can now be prepped for phase I of the clinical trials required for regulatory approval.

Media Release Swiss National Science Foundation (SNSF)

Media Release RocketVax AG

Innovative research into new vaccines against Covid-19 (PDF, 362 kB, 02.12.2021)Volker Thiel, a virologist at the Institute of Virology and Immunology, is following a different approach. He is developing a live-attenuated vaccine, i.e. a vaccine containing a weakened form of the virus that does not make the recipient ill, but still provokes an immune response.

New system developed for rapid SARS-CoV-2 variant characterization and facilitated drug development (PDF, 84 kB, 18.10.2021)Researchers led by the Nobel Laureate Charles Rice of The Rockefeller University and Volker Thiel of the University of Bern and Institute of Virology and Immunology have developed a non-contagious model of SARS-CoV-2 that makes it easier, faster and safer to study the virus and new variants. In addition, the realistic model can be used to better test drugs.

Good knowledge of the BVD virus is important for its eradication (PDF, 110 kB, 17.09.2021)The eradication of bovine viral diarrhoea (BVD) is progressing, but the virus has not yet completely disappeared in Switzerland. The IVI, the FSVO, the Veterinary Office of Solothurn Canton and the Veterinary Office of the Original Cantons recently published the current body of knowledge on BVD virus and its control. The last infection chains must now be detected as quickly as possible and BVD-free herds protected against reinfection.

In vitro Zoo helps in understanding Sars-CoV-2 (PDF, 87 kB, 19.07.2021)A team of researchers from the Institute for Infectious Diseases (IFIK) at the University of Bern and the Institute of Virology and Immunology (IVI) have used a unique collection of advanced cell culture models of cells lining the airways from various domesticated and wildlife animals to determine which animals are susceptibly to SARS-CoV-2 infection.

BioCopy Holding AG and Institute of Virology and Immunology (IVI) announce collaboration on African swine fever (PDF, 103 kB, 21.04.2021)BioCopy Holding AG and the Institute of Virology and Immunology (IVI) have announced to collaborate in researching a vaccine and developing new diagnostic methods in the fight against African swine fever (ASF). Fatal to pigs and wild boar, the ASF virus reached Eastern Germany in 2020 after circulating in Eastern Europe for many years.

Why SARS-CoV-2 replicates better in the upper respiratory tract (PDF, 118 kB, 27.04.2021)A team of researchers from the Institute for Infectious Diseases (IFIK) at the University of Bern and the Federal Institute of Virology and Immunology (IVI) have assessed virus growth and activation of the cellular defense mechanisms in the respiratory tract. They have shown that natural temperature differences that exist in the upper and lower respiratory tract have a profound influence on SARS-CoV-2 replication and subsequent innate immune activation in human cells. The findings can help to develop antiviral drugs and preventive measures.

Media release

Media release

Java script is required to display press releases. If you are unable or unwilling to activate Java script you may use the link below to access the Federal Administration News Portal, where you can read the announcements.

To the Federal Administration News Portal

Last modification 16.03.2022

Top of page